Summary by Moomoo AI
Novavax, Inc., a biotechnology company known for its vaccine development, has filed a definitive proxy statement with the United States Securities and Exchange Commission (SEC). The filing, made under Schedule 14A, is a requirement for companies that are soliciting shareholder votes. Novavax has confirmed that the proxy statement is definitive, indicating that it contains all the necessary information for shareholders to make informed decisions regarding the matters to be voted on. The company has also noted that no filing fee is required for this submission.